171 related articles for article (PubMed ID: 3428349)
1. BN 52021 displaces [3H]paf-acether from, and inhibits its binding to intact human platelets.
Korth R; Benveniste J
Eur J Pharmacol; 1987 Oct; 142(3):331-41. PubMed ID: 3428349
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three paf-acether receptor antagonist ginkgolides.
Korth R; Nunez D; Bidault J; Benveniste J
Eur J Pharmacol; 1988 Jul; 152(1-2):101-10. PubMed ID: 2850196
[TBL] [Abstract][Full Text] [Related]
3. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021.
Lachachi H; Plantavid M; Simon MF; Chap H; Braquet P; Douste-Blazy L
Biochem Biophys Res Commun; 1985 Oct; 132(2):460-6. PubMed ID: 2998370
[TBL] [Abstract][Full Text] [Related]
5. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds.
Baroggi N; Etienne A; Braquet P
Agents Actions Suppl; 1986; 20():87-97. PubMed ID: 3028108
[TBL] [Abstract][Full Text] [Related]
6. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
7. Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets.
Simon MF; Chap H; Braquet P; Douste-Blazy L
Thromb Res; 1987 Feb; 45(4):299-309. PubMed ID: 3576518
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.
Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L
Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421
[TBL] [Abstract][Full Text] [Related]
9. Interference of BN 52021 (ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pig.
Desquand S; Touvay C; Randon J; Lagente V; Vilain B; Maridonneau-Parini I; Etienne A; Lefort J; Braquet P; Vargaftig BB
Eur J Pharmacol; 1986 Aug; 127(1-2):83-95. PubMed ID: 3019727
[TBL] [Abstract][Full Text] [Related]
10. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets.
Adnot S; Joseph D; Vargaftig BB
Agents Actions; 1987 Jun; 21(1-2):195-202. PubMed ID: 3115070
[TBL] [Abstract][Full Text] [Related]
11. Binding kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets.
Kloprogge E; Akkerman JW
Biochem J; 1984 Nov; 223(3):901-9. PubMed ID: 6150705
[TBL] [Abstract][Full Text] [Related]
12. Specific binding of [3H]-1-O-octadecyl Paf-acether to washed human platelets.
Tuffin DP; Davey P; Dyer RL; Lunt DO; Wade PJ
Adv Exp Med Biol; 1985; 192():83-96. PubMed ID: 3834789
[TBL] [Abstract][Full Text] [Related]
13. PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
Robaut C; Durand G; James C; Lave D; Sedivy P; Floch A; Mondot S; Pacot D; Cavero I; Le Fur G
Biochem Pharmacol; 1987 Oct; 36(19):3221-9. PubMed ID: 2822048
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of the binding of platelet-activating factor to platelets of different animal species.
Iñarrea P; Gomez-Cambronero J; Nieto M; Crespo MS
Eur J Pharmacol; 1984 Oct; 105(3-4):309-15. PubMed ID: 6510472
[TBL] [Abstract][Full Text] [Related]
15. Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.
Domingo MT; Piro F; Broquet C; Auclair E; Chabrier PE; Braquet P
Lipids; 1992 Aug; 27(8):582-6. PubMed ID: 1328798
[TBL] [Abstract][Full Text] [Related]
16. Activation of guinea pig eosinophils by human recombinant IL-5. Selective priming to platelet-activating factor-acether and interference of its antagonists.
Coëffier E; Joseph D; Vargaftig BB
J Immunol; 1991 Oct; 147(8):2595-602. PubMed ID: 1655895
[TBL] [Abstract][Full Text] [Related]
17. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets.
Wade PJ; Lunt DO; Lad N; Tuffin DP; McCullagh KG
Thromb Res; 1986 Jan; 41(2):251-62. PubMed ID: 3961730
[TBL] [Abstract][Full Text] [Related]
18. Platelet-activating factor antagonists treatment protects against postischemic acute renal failure in rats.
López-Farré A; Bernabeu F; Gómez-Garre D; Ramon y Cajal S; Braquet P; López-Novoa JM
J Pharmacol Exp Ther; 1990 Apr; 253(1):328-33. PubMed ID: 2329516
[TBL] [Abstract][Full Text] [Related]
19. Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro.
Berdel WE; Korth R; Reichert A; Houlihan WJ; Bicker U; Nomura H; Vogler WR; Benveniste J; Rastetter J
Anticancer Res; 1987; 7(6):1181-7. PubMed ID: 3442414
[TBL] [Abstract][Full Text] [Related]
20. The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021.
Baranes J; Hellegouarch A; Le Hegarat M; Viossat I; Auguet M; Chabrier PE; Braquet P
Pharmacol Res Commun; 1986 Aug; 18(8):717-37. PubMed ID: 3763677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
